129 related articles for article (PubMed ID: 31929428)
1. Association of Alemtuzumab Induction With a Significantly Lower Incidence of GVHD Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center.
Vianna R; Farag A; Gaynor JJ; Selvaggi G; Tekin A; Garcia J; Pierce C; Beduschi T
Transplantation; 2020 Oct; 104(10):2179-2188. PubMed ID: 31929428
[TBL] [Abstract][Full Text] [Related]
2. Association of More Intensive Induction With Less Acute Rejection Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center.
Vianna R; Farag A; Gaynor JJ; Selvaggi G; Tekin A; Garcia J; Beduschi T
Transplantation; 2020 Oct; 104(10):2166-2178. PubMed ID: 31929425
[TBL] [Abstract][Full Text] [Related]
3. Post-intestine transplant graft-vs-host disease associated with inclusion of a liver graft and with a high mortality risk.
Clouse JW; Kubal CA; Fridell JA; Pearsall EJ; Mangus RS
Clin Transplant; 2019 Jan; 33(1):e13409. PubMed ID: 30222903
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival.
Finazzi MC; Boschini C; Craddock C; Rambaldi A; Ward J; Malladi RK
Br J Haematol; 2020 Feb; 188(4):550-559. PubMed ID: 31713861
[TBL] [Abstract][Full Text] [Related]
6. Challenges with Intestine and Multivisceral Re-Transplantation: Importance of Timing of Re-Transplantation and Optimal Immunosuppression.
Kubal CA; Pennington C; Fridell J; Ekser B; Muhaylov P; Mangus R
Ann Transplant; 2018 Feb; 23():98-104. PubMed ID: 29402878
[TBL] [Abstract][Full Text] [Related]
7. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
9. Current status of graft-versus-host disease after intestinal transplantation.
Ganoza A; Mazariegos GV; Khanna A
Curr Opin Organ Transplant; 2019 Apr; 24(2):199-206. PubMed ID: 30762668
[TBL] [Abstract][Full Text] [Related]
10. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
11. Experimental short-term immunosuppression after bowel transplantation and donor-specific bone marrow infusion.
Harmon JV; Gruessner AC; Nakhleh RE; Zhang K; Gruessner RW
Arch Surg; 2001 Jul; 136(7):817-21. PubMed ID: 11448397
[TBL] [Abstract][Full Text] [Related]
12. Does Induction Type Influence Outcomes in Kidney Transplant Recipients at Different Phases of Hepatitis B Infection?
Sureshkumar KK; Chopra B
Exp Clin Transplant; 2019 Aug; 17(4):457-460. PubMed ID: 30066624
[TBL] [Abstract][Full Text] [Related]
13. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.
Neumann T; Schneidewind L; Thiele T; Pink D; Schulze M; Schmidt C; Krüger W
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178248
[TBL] [Abstract][Full Text] [Related]
14. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
15. Clinical intestinal transplantation: new perspectives and immunologic considerations.
Abu-Elmagd K; Reyes J; Todo S; Rao A; Lee R; Irish W; Furukawa H; Bueno J; McMichael J; Fawzy AT; Murase N; Demetris J; Rakela J; Fung JJ; Starzl TE
J Am Coll Surg; 1998 May; 186(5):512-25; discussion 525-7. PubMed ID: 9583691
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
Resende CB; Rezende BM; Bernardes PT; Teixeira GM; Teixeira MM; Pinho V; Bittencourt H
Braz J Med Biol Res; 2017 Feb; 50(2):e5566. PubMed ID: 28198910
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases.
Nagai S; Mangus RS; Anderson E; Ekser B; Kubal CA; Fridell JA; Tector AJ
Transplantation; 2016 Feb; 100(2):451-60. PubMed ID: 26247555
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
